Biotechnology Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine – Madrigal Pharmaceuticals (NASDAQ:MDGL) Read more
Venture Capital Deal Doldrums: An Era of Inflated Valuations is Over – Los Angeles Business Journal Read more